How Targeted Cancer Drugs Disrupt the Cell Cycle
PLOS: DNA Science
JUNE 22, 2023
The candidate drug, vorasidenib, is a small molecule that inhibits survivin. Cancer cells make too much survivin, with levels increasing as the disease spreads and becomes more aggressive. It delayed disease progression and more than doubled survival time, adding 17 months. Here’s an article from 2002. Blood cancer.
52 
Let's personalize your content